TP53 and lymphoma: Targeting p53-MDM2/MDMX interactions, a series of stapled peptides originating from different stapling chemistries have been designed, of which the notable example ALRN-6924, a hydrocarbon stapled MDM2/MDMX antagonist, can reactivate the p53 pathway, and this drug candidate has entered phase II clinical trials for advanced solid tumors and lymphomas 17.